Department of Oncology and Haematology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Department of Oncology and Haematology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Int J Infect Dis. 2019 Mar;80:134-136. doi: 10.1016/j.ijid.2019.01.002. Epub 2019 Jan 11.
Ruxolitinib is a JAK-1/JAK-2 inhibitor indicated for the treatment of polycythemia vera and primary or secondary myelofibrosis. Only one patient (0.2%) was diagnosed with tuberculosis among the 485 patients receiving ruxolitinib in the four pivotal trials. Fourteen cases of tuberculosis have since been reported. We observed two (3%) mycobacterial infections (one due to Mycobacterium tuberculosis and one due to Mycobacterium avium complex) in our cohort of 65 patients receiving ruxolitinib. This observation suggests that the rate of mycobacterial infection might be higher than that observed in the pivotal trials and that atypical mycobacterial infections can also occur.
芦可替尼是一种 JAK-1/JAK-2 抑制剂，适用于治疗真性红细胞增多症和原发性或继发性骨髓纤维化。在四项关键试验中接受芦可替尼治疗的 485 名患者中，只有 1 名（0.2%）患者被诊断患有结核病。此后已报告了 14 例结核病病例。我们观察到在接受芦可替尼治疗的 65 名患者队列中，有两例（3%）分枝杆菌感染（一例由结核分枝杆菌引起，一例由鸟分枝杆菌复合群引起）。这一观察结果表明，分枝杆菌感染的发生率可能高于关键试验中观察到的水平，并且也可能发生非典型分枝杆菌感染。
